World's Best Scientists 2026 revealed!
Michael A. Vogelbaum

Michael A. Vogelbaum

D-Index & Metrics

Medicine

D-Index
96
Citations
37857
World Ranking
9579
National Ranking
4933

Michael A. Vogelbaum publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael A. Vogelbaum sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 516 publications — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael A. Vogelbaum D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael A. Vogelbaum sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 96 D-Index — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael A. Vogelbaum is affiliated with the Cleveland Clinic in the United States and has contributed extensively to the field of medicine, with a focus on oncology and neurology. Their research primarily addresses the diagnosis, treatment, and management of brain tumors and related conditions.

The main fields of study within Vogelbaum's work include Medicine, with a notable number of publications in Genetics, Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, and Neurology. The scientist's research interests align with key topics such as:

  • Glioma Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Meningioma and schwannoma management
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Immune cells in cancer

Their scholarly output includes numerous publications across several respected journals. Frequent publication venues are:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Neuro-Oncology Advances
  • Journal of Neuro-Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)

Among Vogelbaum's recent papers are:

  • "Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline," 2021, Journal of Clinical Oncology
  • "RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults," 2023, Journal of Clinical Oncology
  • "Federated learning enables big data for rare cancer boundary detection," 2022, Nature Communications
  • "Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group," 2022, Neuro-Oncology
  • "Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial," 2023, Nature Medicine

Vogelbaum has collaborated frequently with several researchers, indicating active engagement in multi-author projects. Regular coauthors include:

  • Martin J. van den Bent
  • Michael Weller
  • Patrick Y. Wen
  • Peter Forsyth
  • Arnold B. Etame

Best Publications

  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

    Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy

  • A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

    Mark R. Gilbert;James J. Dignam;Terri S. Armstrong;Terri S. Armstrong;Jeffrey Scott Wefel

  • Response assessment criteria for brain metastases: proposal from the RANO group

    Nancy U Lin;Eudocia Q Lee;Hidefumi Aoyama;Igor J Barani

  • Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

    Nathalie L. Albert;Michael Weller;Bogdana Suchorska;Norbert Galldiks

  • Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

    Benjamin M. Ellingson;Martin Bendszus;Martin Bendszus;Jerrold Boxerman;Daniel Barboriak

  • Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

    Leland Rogers;Igor Barani;Marc Chamberlain;Thomas J. Kaley

  • Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline

    May N. Tsao;Dirk Rades;Andrew Wirth;Simon S. Lo

  • Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

    M. J. van den Bent;J. S. Wefel;D. Schiff;M. J. B. Taphoorn

  • Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

    Sandeep Kunwar;Susan Chang;Manfred Westphal;Michael Vogelbaum

  • Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.

    Shaik Ohidar Rahaman;Phyllis C Harbor;Olga Chernova;Gene H Barnett

  • Response Assessment in Neuro-Oncology Clinical Trials.

    Patrick Y. Wen;Susan M. Chang;Martin J. Van den Bent;Michael A. Vogelbaum

  • Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma

    Matthew M. Grabowski;Pablo F. Recinos;Amy S. Nowacki;Jason L. Schroeder

  • Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

    Martin J van den Bent;Brigitta Baumert;Sara C Erridge;Michael A Vogelbaum;Michael A Vogelbaum

  • Serum S100β: A Noninvasive Marker of Blood-Brain Barrier Function and Brain Lesions

    Andrew A. Kanner;Andrew A. Kanner;Nicola Marchi;Vincent Fazio;Marc R. Mayberg;Marc R. Mayberg

  • Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma

    Baisakhi Raychaudhuri;Patricia Rayman;Joanna Ireland;Jennifer Ko

  • End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.

    Martin J. van den Bent;Michael A. Vogelbaum;Patrick Y. Wen;David R. Macdonald

  • Poor drug distribution as a possible explanation for the results of the PRECISE trial.

    John H. Sampson;Gary Archer;Christoph Pedain;Eva Wembacher-Schröder

  • Intermediate-risk meningioma: Initial outcomes from NRG Oncology RTOG 0539

    Leland Rogers;Peixin Zhang;Michael A Vogelbaum;Arie Perry

  • Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) working group

    Michael A. Vogelbaum;Sarah Jost;Manish K. Aghi;Amy B. Heimberger

  • Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin

    Michael A. Vogelbaum;Lilyana Angelov;Shih Yuan Lee;Liang Li

Frequent Co-Authors

John H. Suh
John H. Suh Cleveland Clinic
Gene H. Barnett
Gene H. Barnett Cleveland Clinic
Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Martin J. van den Bent
Martin J. van den Bent Erasmus University Rotterdam
Susan M. Chang
Susan M. Chang University of California, San Francisco
Patrick Y. Wen
Patrick Y. Wen Harvard University
Minesh P. Mehta
Minesh P. Mehta University of Maryland, Baltimore
Justin D. Lathia
Justin D. Lathia Cleveland Clinic Lerner College of Medicine
Santosh Kesari
Santosh Kesari University of California, San Diego
Michael Weller
Michael Weller University of Zurich

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of health-related careers—many of which can be accessed through flexible online programs. If you want a fast start in patient care, lpn online programs allow you to qualify as a Licensed Practical Nurse in less time, providing both job security and practical experience.

For those interested in advanced practice and mental health, psych np programs offer an accelerated path to becoming a Psychiatric Mental Health Nurse Practitioner. These programs are designed for nurses aiming to expand their scope of practice and serve in high-demand specialties.

Not all medical careers require direct patient care. With a health care administration online degree, you can prepare for leadership and management roles in various health settings. Many students continue their education with the most affordable mha programs, which focus on advanced administrative skills while offering flexible online study and cost-effective options.

These related online degrees and career pathways make it easier to find your niche in healthcare and build a fulfilling career on your terms.

Best Scientists Citing Michael A. Vogelbaum

Trending Scientists

Recently Published Articles